A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
AVANOS MEDICAL, INC.
AVNS
$1.2B
Mkt Cap
$24.99
+0.04%
AVANOS MEDICAL, INC. (AVNS) has a 5-year average return on invested capital (ROIC) of -7.7%. This is below average and may indicate limited pricing power.
AVANOS MEDICAL, INC. (AVNS) has a market capitalization of $1.2B. It is classified as a small-cap stock.
AVANOS MEDICAL, INC. (AVNS) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.21%.
AVANOS MEDICAL, INC. (AVNS) operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, within the Healthcare sector.
AVANOS MEDICAL, INC. (AVNS) reported annual revenue of $701 million in its most recent fiscal year, based on SEC EDGAR filings.
AVANOS MEDICAL, INC. (AVNS) has a net profit margin of -10.4%. The company is currently unprofitable.
AVANOS MEDICAL, INC. (AVNS) generated $43 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Table of Contents Avanos Medical, Inc. is a medical technology company focused on delivering clinically superior medical device solutions that help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today’s most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. Unless the context indicates otherwise, the terms “Avanos,” “the Company,” “we,” “our” and “us” refer to Avanos Medical, Inc. and its consolidated subsidiaries. We were originally incorporated in Delaware in 2014.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 716M | 701M | 688M | 673M | 684M | 587M |
| Net Income | -74M | -73M | -392M | -62M | 51M | 6.3M |
| EPS | $-1.61 | $-1.57 | $-8.53 | $-1.32 | $1.07 | $0.13 |
| Free Cash Flow | 7.5M | 43M | 83M | 15M | 72M | 66M |
| ROIC | -6.1% | -8.0% | -33.4% | 0.3% | 2.1% | 0.4% |
| Gross Margin | 50.0% | 50.5% | 55.4% | 56.4% | 57.6% | 51.0% |
| Debt/Equity | 0.13 | 0.17 | 0.21 | 0.17 | 0.21 | 0.15 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -63M | -62M | -396M | 4.2M | 36M | -39M |
| Operating Margin | -8.8% | -8.8% | -57.6% | 0.6% | 5.2% | -6.6% |
| ROE | -9.5% | -9.1% | -38.0% | -4.9% | 3.9% | 0.5% |
| Shares Outstanding | 47M | 46M | 46M | 47M | 47M | 48M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 1.7B | 509M | 566M | 612M | 652M | 698M | 715M | 587M | 684M | 673M | 688M | 701M | 716M |
| Gross Margin | 32.8% | 50.6% | 52.5% | 55.1% | 59.9% | 57.7% | 51.9% | 51.0% | 57.6% | 56.4% | 55.4% | 50.5% | 50.0% |
| R&D | 34M | 28M | 38M | 38M | 42M | 38M | 35M | 31M | 29M | 27M | 26M | 23M | 23M |
| SG&A | 425M | 350M | 346M | 322M | 340M | 399M | 333M | 285M | 327M | 335M | 319M | 316M | 318M |
| EBIT | 94M | -136M | -107M | -43M | N/A | -56M | -49M | -39M | 36M | 4.2M | -396M | -62M | -63M |
| Op. Margin | 5.6% | -26.7% | -18.9% | -7.0% | N/A | -8.0% | -6.8% | -6.6% | 5.2% | 0.6% | -57.6% | -8.8% | -8.8% |
| Net Income | 27M | -426M | 40M | 79M | 58M | -46M | -29M | 6.3M | 51M | -62M | -392M | -73M | -74M |
| Net Margin | 1.6% | -83.8% | 7.0% | 13.0% | 8.8% | -6.6% | -4.1% | 1.1% | 7.4% | -9.2% | -57.0% | -10.4% | -10.4% |
| Non-Recurring | -6.7M | 481M | -3.7M | -3.3M | 14M | 29M | 50M | 30M | 7.8M | -43M | 345M | 109M | 109M |
| Returns on Capital | |||||||||||||
| ROIC | 2.8% | -7.8% | 2.4% | 4.6% | N/A | -3.0% | -2.0% | 0.4% | 2.1% | 0.3% | -33.4% | -8.0% | -6.1% |
| ROE | 1.5% | -33.5% | 3.7% | 6.8% | 4.6% | -3.6% | -2.3% | 0.5% | 3.9% | -4.9% | -38.0% | -9.1% | -9.5% |
| ROA | 1.1% | -18.9% | 2.0% | 3.7% | 2.9% | -2.5% | -1.7% | 0.4% | 3.0% | -3.6% | -27.5% | -6.5% | -7.1% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 148M | 98M | 189M | 144M | -146M | -75M | -2.5M | 87M | 91M | 32M | 101M | 75M | 37M |
| Free Cash Flow | 69M | 27M | 160M | 101M | -195M | -125M | -23M | 66M | 72M | 15M | 83M | 43M | 7.5M |
| Owner Earnings | 55M | 18M | 109M | 72M | -190M | -122M | -58M | 36M | 27M | -30M | 41M | 23M | -15M |
| CapEx | 79M | 70M | 29M | 43M | 49M | 51M | 20M | 21M | 19M | 18M | 18M | 32M | 29M |
| Maint. CapEx | 85M | 65M | 65M | 60M | 34M | 37M | 43M | 38M | 48M | 46M | 46M | 39M | 40M |
| Growth CapEx | 0 | 5.0M | 0 | 0 | 16M | 14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 85M | 65M | 65M | 60M | 34M | 37M | 43M | 38M | 48M | 46M | 46M | 39M | 40M |
| CapEx/OCF | N/A | 72.1% | 15.4% | 30.0% | N/A | N/A | N/A | 24.1% | 21.2% | 54.9% | 17.7% | 42.3% | 79.6% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 1.0M | 900K | 2.5M | 900K | 3.6M | 900K | 12M | 46M | 19M | 13M | 3.3M | 2.4M |
| Buyback Yield | N/A | 0.1% | 0.1% | 0.1% | 0.0% | 0.2% | 0.0% | 0.7% | 3.6% | 1.8% | 1.7% | 0.6% | 0.2% |
| Stock-Based Comp | 7.9M | 14M | 15M | 13M | 11M | 11M | 12M | 13M | 16M | 16M | 14M | 13M | 13M |
| Debt Repayment | 14M | 51M | 0 | 0 | 339M | 200K | 250M | 0 | 127M | 4.7M | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | 478M | 449M | 465M | 361M | -137M | 120M | 137M | 69M | 149M | 121M | 63M | 39M | 33M |
| Cash & Equiv. | 149M | 130M | 114M | 220M | 385M | 205M | 112M | 119M | 128M | 88M | 108M | 90M | 66M |
| Long-Term Debt | 623M | 578M | 579M | 541M | 248M | 248M | 180M | 130M | 226M | 159M | 125M | 90M | 87M |
| Debt/Equity | 0.42 | 0.55 | 0.53 | 0.48 | 0.19 | 0.26 | 0.20 | 0.15 | 0.21 | 0.17 | 0.21 | 0.17 | 0.13 |
| Interest Coverage | 15.7 | -4.1 | -3.3 | -1.4 | N/A | -3.7 | -3.1 | -11.8 | 3.5 | 0.3 | -32.5 | -7.9 | -7.9 |
| Equity | 1.5B | 1.1B | 1.1B | 1.2B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.2B | 829M | 778M | 782M |
| Total Assets | 2.5B | 2.0B | 2.1B | 2.2B | 1.8B | 1.8B | 1.7B | 1.6B | 1.8B | 1.7B | 1.2B | 1.1B | 1.1B |
| Total Liabilities | 1.0B | 945M | 969M | 981M | 536M | 534M | 416M | 333M | 496M | 456M | 326M | 296M | 268M |
| Intangibles | 108M | 83M | 168M | 149M | 168M | 184M | 158M | 141M | 234M | 240M | 112M | 118M | 115M |
| Retained Earnings | 7.3M | -419M | -379M | -300M | -242M | -288M | -316M | -304M | -253M | -315M | -707M | -780M | -775M |
| Working Capital | 328M | 361M | 269M | 771M | 449M | 326M | 301M | 288M | 433M | 252M | 228M | 190M | 194M |
| Current Assets | 684M | 676M | 594M | 1.2B | 714M | 539M | 467M | 428M | 624M | 487M | 393M | 355M | 325M |
| Current Liabilities | 356M | 315M | 324M | 390M | 264M | 213M | 166M | 139M | 191M | 235M | 166M | 165M | 131M |
| Per Share Data | |||||||||||||
| EPS | 0.58 | -9.15 | 0.85 | 1.69 | 1.22 | -0.96 | -0.61 | 0.13 | 1.07 | -1.32 | -8.53 | -1.57 | -1.61 |
| Owner EPS | 1.17 | 0.39 | 2.32 | 1.54 | -4.02 | -2.55 | -1.21 | 0.74 | 0.58 | -0.63 | 0.90 | 0.50 | -0.33 |
| Book Value | 31.91 | 22.65 | 23.55 | 25.90 | 27.52 | 26.62 | 26.55 | 26.22 | 27.36 | 26.41 | 18.02 | 16.76 | 16.76 |
| Cash Flow/Share | 3.17 | 2.09 | 4.03 | 3.07 | -3.09 | -1.56 | -0.05 | 1.80 | 1.93 | 0.69 | 2.19 | 1.61 | -0.75 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 46.7M | 46.6M | 46.8M | 46.9M | 47.1M | 47.8M | 47.5M | 48.5M | 47.2M | 46.8M | 46.0M | 46.4M | 46.7M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | 43.9 | 27.6 | 35.5 | N/A | N/A | 262.8 | 25.0 | N/A | N/A | N/A | -15.5 |
| P/FCF | 28.1 | 58.2 | 10.9 | 21.7 | N/A | N/A | N/A | 25.0 | 17.6 | 73.0 | 8.8 | 12.3 | 155.5 |
| EV/EBIT | N/A | N/A | N/A | N/A | 20.5 | N/A | N/A | 148.9 | 35.1 | 253.9 | N/A | N/A | N/A |
| Price/Book | 1.3 | 1.5 | 1.6 | 1.8 | 1.6 | 1.3 | 1.8 | 1.3 | 1.0 | 0.9 | 0.9 | 0.7 | 1.5 |
| Price/Sales | 22.9 | 1.2 | 2.6 | 3.2 | 3.9 | 2.8 | 2.2 | 2.5 | 1.9 | 1.7 | 1.4 | 0.8 | 1.6 |
| FCF Yield | 3.6% | 1.7% | 9.1% | 4.6% | -9.5% | -7.8% | -1.0% | 4.0% | 5.7% | 1.4% | 11.3% | 8.1% | 0.6% |
| Market Cap | 1.9B | 1.6B | 1.7B | 2.2B | 2.0B | 1.6B | 2.2B | 1.7B | 1.3B | 1.1B | 732M | 530M | 1.2B |
| Avg. Price | 38.88 | 39.32 | 32.04 | 41.29 | 54.29 | 40.50 | 32.99 | 38.69 | 27.96 | 24.68 | 20.42 | 12.83 | 24.99 |
| Year-End Price | 41.71 | 34.00 | 37.30 | 46.71 | 43.36 | 33.56 | 46.43 | 34.17 | 26.76 | 22.75 | 15.92 | 11.41 | 24.99 |
AVANOS MEDICAL, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 27.0x vs a median of 17.6x. The company's 5-year average gross margin is 54.2%. Total shareholder yield (buybacks) is 0.2%. At current prices, the estimated annualized return to fair value is +20.9%.
AVANOS MEDICAL, INC. (AVNS) has a debt-to-equity ratio of 0.17. This indicates a conservatively financed balance sheet.
AVANOS MEDICAL, INC. (AVNS) reported earnings per share (EPS) of $-1.57 in its most recent fiscal year.
AVANOS MEDICAL, INC. (AVNS) has a return on equity (ROE) of -9.1%. A negative ROE may indicate losses or negative equity.
AVANOS MEDICAL, INC. (AVNS) has a 5-year average gross margin of 54.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for AVANOS MEDICAL, INC. (AVNS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AVANOS MEDICAL, INC. (AVNS) has a book value per share of $16.76, based on its most recent annual SEC filing.